US2018111983A1PendingUtilityA1

Treatment of Fibrodysplasia Ossificans Progressiva

52
Assignee: REGENERON PHARMAPriority: Sep 12, 2014Filed: Aug 28, 2017Published: Apr 26, 2018
Est. expirySep 12, 2034(~8.1 yrs left)· nominal 20-yr term from priority
Inventors:Sarah J. HatsellAris N. EconomidesVincent J. Idone
A61P 43/00A61P 19/00A61P 21/00A61P 19/04A61P 19/08A61K 38/179C07K 16/2863C07K 2319/30A61K 39/39533C07K 16/18C07K 2317/33A61K 2039/505C07K 14/705C07K 16/22C07K 2317/21C07K 2317/24C07K 16/28A61K 39/3955A61K 2300/00A61K 31/138
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A.

Claims

exact text as granted — not AI-modified
1 . A method of treating Fibrodysplasia Ossificans Progressiva (FOP), comprising administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist. 
     
     
         2 - 13 . (canceled) 
     
     
         14 . A method of treating Fibrodysplasia Ossificans Progressiva (FOP), comprising administering to a subject having FOP an effective regime of an activin receptor type 1 (ACVR1) antagonist. 
     
     
         15 - 18 . (canceled) 
     
     
         19 . A method of treating Fibrodysplasia Ossificans Progressiva (FOP), comprising administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist in combination with an activin receptor type 1 (ACVR1) antagonist. 
     
     
         20 - 23 . (canceled) 
     
     
         24 . A method of treating Fibrodysplasia Ossificans Progressiva (FOP), comprising administering to a subject having FOP an effective regime of an antibody against Activin A. 
     
     
         25 . The method of  claim 24 , wherein the antibody competes for binding with antibody comprising the heavy and light chain variable regions of the antibody designated H4H10446P, H4H10430P or A1. 
     
     
         26 . The method of  claim 24 , wherein the antibody comprises the heavy and light chain variable regions of the antibody designated H4H10446P, H4H10430P or A1. 
     
     
         27 . The method of  claim 24 , wherein the antibody is chimeric, veneered, humanized or human antibody. 
     
     
         28 . The method of  claim 24  wherein the antibody is an intact antibody. 
     
     
         29 . The method of  claim 24 , wherein the antibody is a human kappa IgG1 antibody. 
     
     
         30 . The method of  claim 25 , wherein the antibody is a human kappa IgG1 antibody. 
     
     
         31 . The method of  claim 26 , wherein the antibody is a human kappa IgG1 antibody. 
     
     
         32 . The method of  claim 27 , wherein the antibody is a human kappa IgG1 antibody. 
     
     
         33 . The method of  claim 28 , wherein the antibody is a human kappa IgG1 antibody.

Join the waitlist — get patent alerts

Track US2018111983A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.